With the RIDA®PRECISION ABCB1 test you support physicians in the decision of an antidepressant treament in order to choose the best drug in the appropriate dose for any individual patient.
Before initiation of an antidepressant therapy analysis of the ABCB1 genotype is highly recommended. The ABCB1 gene carries a number of variants with unequal impact on clinical outcome. Researchers at the Max Planck Institute of Psychiatry have identified two variants that are best suited to discriminate between favorable and less favorable ABCB1 genotypes with respect to antidepressant treatment outcome. These variants are patent protected (by HMNC Brain Health) for this specific use and implemented in the commercially available RIDA®PRECISION ABCB1 test. The test result advises the doctor which antidepressants should be administered at which dose.
Many clinical studies corroborated that antidepressant treatment guided by the ABCB1 test is superior to “treatment-as-usual”. If the clinically effective antidepressant is chosen a more rapid onset of action and higher remission rates can be expected (Breitenstein et al 2014; Sarginson et al 2010).
For more information, visit www.abcb1-test.de
The RIDA®PRECISION real-time PCR products of human genetic diagnostics allow the dection of predispositions for various hereditary diseases
|HLA-B27||Detection of the HLA-B27 gene*|
|Thrombophilia||Factor II mutation (prothrombin)
Factor V Leiden mutation
|Food intolerance||Hereditary fructose intolerance
Hereditary lactose intolerance
|Hereditary hemochromatosis||Detection of mutations associated with hereditary hemochromatosis|
*no tissue typing
The RIDA®PRECISION real-time PCR products for human genetic diagnostics are soon available.
RIDA®PRECISION real-time PCR tests
- combine real-time PCR detection and multiplex PCR for identifiyng DNA polymorphisms
- deliver fast analysis with a ready to use oligonucleotide mix using fluorescence labeled hydrolysis probes, amplification mix and internal controls
RIDA® is a world-wide recognized trademark of R-Biopharm AG.